Park Medi World Ltd. shares took a beating on Friday, November 13, tumbling 7.7% to an intraday low of ₹236.01 in Mumbai. Traders dumped holdings across early trade. Operating profitability cracked across nearly every fundamental parameter, triggering an immediate selloff despite top-line expansion.
Top-line numbers told an incomplete story. Revenue for the September quarter expanded 24.6% to ₹511 crore, up from ₹410 crore posted during the corresponding quarter of the prior fiscal. But operational costs ate away that growth. Net profit plummeted 29.7% year-on-year to ₹52 crore against ₹74 crore in the year-ago period, according to the regulatory filing submitted to exchanges.
Earnings before interest, taxes, depreciation, and amortization dropped 9.5% to ₹101.8 crore, compared to ₹112.5 crore logged during the same period last year. The fallout on profitability was immediate. Operating margins shrank by 740 basis points, down from 27.4% a year ago to 20%.
| Metric | Q2 Current Fiscal | Q2 Previous Fiscal | YoY Change |
|---|---|---|---|
| Revenue | ₹511 crore | ₹410 crore | +24.6% |
| Net Profit | ₹52 crore | ₹74 crore | -29.7% |
| EBITDA | ₹101.8 crore | ₹112.5 crore | -9.5% |
| EBITDA Margin | 20.0% | 27.4% | -740 bps |
The market reaction was merciless. Institutional desks and retail participants unwound long positions as margin compression outpaced the top-line gain.
Market Context: Earnings season across the domestic bourses reached a crescendo on November 13, with corporate giants including Grasim, Eicher Motors, ABB India, Tata Motors PV, RVNL, Indo-MIM, Godrej Industries, and healthcare peer Manipal Health unveiling quarterly financial scorecards. Against this crowded tape, Park Medi World stood out for its sharp operational squeeze.
Yet the bigger picture reveals substantial capital gains for patient holders. While the stock shed 4% over the past six months and ticked up just 1% in the past 30 days, it retains a 58.3% advance across 2026 so far.
Park Medi World made its market debut in December 2025 at a 4% discount to its initial public offering price, listing at ₹158.80 per share against an issue price of ₹162. Even after Friday's intraday decline, the stock trades 46% above its original issue price and 50% above its listing level. Institutional desks will now watch management's upcoming disclosures to see whether the 740-basis-point margin erosion was a transient bump or the start of deeper operating stress.